AI model predicts future spread of SARS-CoV-2 variants using genomic data

NewsGuard 100/100 Score

In a recent study published in PNAS Nexus, researchers developed a risk evaluation model using machine learning to predict the future distribution trajectory of newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants using genomic and epidemiological data.

Study: Predicting the spread of SARS-CoV-2 variants: An artificial intelligence-enabled early detection. Image Credit: Peter Kneiz / Shutterstock.com Study: Predicting the spread of SARS-CoV-2 variants: An artificial intelligence-enabled early detection. Image Credit: Peter Kneiz / Shutterstock.com

How are novel SARS-CoV-2 strains identified?

The United States Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) are monitoring the emergence of novel SARS-CoV-2 variants to inform pandemic preparedness. However, identifying the small proportion of mutations that cause a new wave remains difficult.

Academic researchers have developed various models to forecast pandemic trajectory; however, none of these systems have been focused on variant-specific dissemination. Aside from monitoring the genetic development of mutant SARS-CoV-2 strains, genetic characteristics have not been included in current epidemiological modeling to reflect the infection trajectory.

About the study

In the present study, researchers used an artificial intelligence (AI)-based approach to evaluate nine million SARS-CoV-2 genomic sequences in 30 countries and reveal temporal patterns of variants producing large infection waves. The model used data from the Pango lineage, Global Initiative on Sharing Avian Influenza Data (GISAID), coronavirus disease 2019 (COVID-19) cases, vaccination rates, and non-pharmaceutical interventions.

The analysis focused on 30 nations that reported the most SARS-CoV-2 genomic sequences in March 2022. These 30 nations account for nine million out of 9.5 million genomic sequences recorded in GISAID since the beginning of the pandemic.

By March 19, 2022, 1,151 unique variants had been consistently detected in the included nations, with a median of 72 variants identified in each country since the pandemic began. The technique is consistent with CDC and WHO wave classifications based on the variants responsible for infections.

Multiple alterations in SARS-CoV-2 proteins compared to the wild-type reference strain identified in Wuhan in early January 2020 distinguished each new variant. The current study considered all conceivable changes in a genomic sequence, such as base substitutions, deletions, and insertions. The approach created a new distance measure between distinct variants by combining the Jaccard distance metric with a variant-specific list of mutations computed by dividing the number of unique mutations in a variant by the number of mutations in another SARS-CoV-2 variant.

The researchers also provided two measures for characterizing variant diversity across time, including variant entropy and heterogeneity. Variant entropy was motivated by applying the thermodynamic concept of entropy in ecological systems to compare low and high entropy states, which correlates to the number of cocirculating variants.

The model aimed to detect SARS-CoV-2 variants that have produced over 1,000 cases for every one million individuals within three months of their detection. Moreover, 31 predictive factors were incorporated into the model that captures the genomic characteristics of novel variants, their early distribution trajectory, and non-pharmaceutical and vaccination initiatives implemented during the period of variant transmission. These traits were used to estimate variant infectivity using machine learning.

Study findings

Risk scores were assigned to all SARS-CoV-2 variants and converted into binary predictions in training datasets to optimize model specificity and sensitivity. After one week of observation, the model can detect 73% of the variants that would trigger a COVID-19 wave of over 1,000 infections in the following three months. With a two-week observation period, this performance rises to 80%.

The out-of-sample area under the curve (AUC) values for the model were 86% for one-week forecasts and 91% for two-week predictions. The top three dominant variants were generally responsible for most instances during the relevant wave and had a total share of 71% throughout all waves.

Spike, nucleocapsid (N), and non-structural protein (NSP) proteins had the most mutations, with median numbers per variant in each nation of 10, three, and 14, respectively. With a median inter-wave distance of 0.9, the initial dominant variant in each wave contained highly unique mutations compared to variants circulating in the preceding wave.

The waves were divided into three groups, including Before-1 and Before-2, which ended before the nationwide vaccination campaign commencement; transition, which began before the vaccination campaign but ended after it; and After-1 and After-2, which commenced after the campaign. Wave-entropy values increased by a small statistically significant amount from Before-2 to Before-1 waves but remained comparable from Before-1 to Transition waves, with a median of 0.5.

Most variants, including those with the highest infectivity, continue to cause infections within two weeks after identification, with a median value of 2.5 COVID-19 cases for every one million individuals. Furthermore, variants causing a similar extent of infections in two weeks may have a significantly different transmission trajectory after three months.

Conclusions

The study findings highlight the development of a prediction model based on nine million genetic sequences from 30 countries to anticipate the emergence of novel SARS-CoV-2 variants. With AUC values of 86% and 91%, the model detected infectious variants as early as one week and two weeks after their detection, respectively.

These observations indicate that novel variants acquire mutations to reinfect or target new population subsets of previously immune individuals. The improved prediction accuracies of the standard models underscore the need to integrate genetic variables into more sensitive models.

Journal reference:
  • Levi, R., El Ghali, Z., & Shoshy, A. (2024). Predicting the spread of SARS-CoV-2 variants: An artificial intelligence-enabled early detection. PNAS Nexus 3(1). doi:10.1093/pnasnexus/pgad424
Pooja Toshniwal Paharia

Written by

Pooja Toshniwal Paharia

Dr. based clinical-radiological diagnosis and management of oral lesions and conditions and associated maxillofacial disorders.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Toshniwal Paharia, Pooja Toshniwal Paharia. (2024, January 04). AI model predicts future spread of SARS-CoV-2 variants using genomic data. News-Medical. Retrieved on April 27, 2024 from https://www.news-medical.net/news/20240104/AI-model-predicts-future-spread-of-SARS-CoV-2-variants-using-genomic-data.aspx.

  • MLA

    Toshniwal Paharia, Pooja Toshniwal Paharia. "AI model predicts future spread of SARS-CoV-2 variants using genomic data". News-Medical. 27 April 2024. <https://www.news-medical.net/news/20240104/AI-model-predicts-future-spread-of-SARS-CoV-2-variants-using-genomic-data.aspx>.

  • Chicago

    Toshniwal Paharia, Pooja Toshniwal Paharia. "AI model predicts future spread of SARS-CoV-2 variants using genomic data". News-Medical. https://www.news-medical.net/news/20240104/AI-model-predicts-future-spread-of-SARS-CoV-2-variants-using-genomic-data.aspx. (accessed April 27, 2024).

  • Harvard

    Toshniwal Paharia, Pooja Toshniwal Paharia. 2024. AI model predicts future spread of SARS-CoV-2 variants using genomic data. News-Medical, viewed 27 April 2024, https://www.news-medical.net/news/20240104/AI-model-predicts-future-spread-of-SARS-CoV-2-variants-using-genomic-data.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study highlights how age affects nasal cell response to SARS-CoV-2